The evolution of melanoma resistance reveals therapeutic opportunities.
about
Resistant mechanisms to BRAF inhibitors in melanomaCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapyThe PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient miceEvolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaA stress-induced early innate response causes multidrug tolerance in melanoma.The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells.Genome-scale CRISPR pooled screens.Applying evolutionary genetics to developmental toxicology and risk assessment.Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibitionMelanoma tumor cell heterogeneity: a molecular approach to study subpopulations expressing the embryonic morphogen nodal.Metronomics: towards personalized chemotherapy?Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".Somatic driver mutations in melanoma.Improving patient outcomes to targeted therapies in melanoma.The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC/5FC therapy in human melanoma xenograft model.Expression and clinicopathological significance of microRNA-21 and programmed cell death 4 in malignant melanoma.Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.TERT promoter mutations in melanoma survival.Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells.Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Tumour heterogeneity and resistance to cancer therapies.Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.
P2860
Q26739717-FCA0A81B-22F4-4D4B-AAA4-6C3145434DC5Q26769870-61AF848A-306F-4707-83A6-BDDF805443CBQ33874466-F3AE6752-4EFC-4390-A85A-16D661100DBCQ34608239-01DBCEC7-22E2-4CDD-8A21-A8DC3355605CQ34662452-737014ED-B3FD-4ABF-B951-A9F50D7148AEQ34667825-623CCB70-72EB-4B0A-9AEB-79C9FEDB40E6Q34786402-963A2F79-119B-455B-AF09-DA579C1DC99FQ35639898-AA759B8F-2F79-418E-B22C-BD7D2F43E67DQ35857502-C27E993F-B8BC-4D13-8B1D-5634CDB620EFQ36040827-0679C275-3E6A-4E29-939A-DD2A622DEF2AQ36299276-E50A29D9-D5D1-494D-BC2F-9E501B3DACABQ37716027-FB781E41-4F4B-42ED-8D78-C88FD50D059AQ38208594-8E5E1933-0E10-4CEE-A428-CF3C807FAC7CQ38218923-03F8F3BF-7B84-4C5C-B5DA-9FEF78F9C8BAQ38233339-76DCACEA-B430-4920-A635-FB37CB998FF2Q38764368-320A6388-8388-4528-B09D-55B466934E35Q38823508-5D8B8B33-9BAC-4368-97E1-4022E5B961F0Q38843111-2FAF5CCA-3554-4E5D-A61D-7A3BD5CF6565Q38972307-C8DF2691-D04F-42DB-909D-7F953EDDF5A4Q38987650-01BFF25F-1EFF-4146-ADE1-EAD813B8577EQ39069585-BACC9B8C-F5EB-42F3-8489-A9161B261604Q39319162-F599FA01-5C4D-41A4-94C8-47468CCED37AQ39620395-95C776E6-E1CE-49BA-8195-0AEA317A94D0Q39998496-CB99A9BA-A74A-4486-9BB3-9C8C7F013B64Q40847850-0AD4F094-5BF2-4E1D-B2CB-1D093368E810Q42474003-44DD5A1C-ACB3-4C1B-8B03-43119ABC36C0Q42712113-1F3B0737-ECB8-4DDE-ABC9-4C111609C350Q43147493-61C6D633-0F63-4AF4-8677-802B12D7715AQ50112440-E7617697-69D8-4E90-9908-936F50621ADDQ53688956-05D483CD-2E76-4063-A94C-B80DA05C5FEE
P2860
The evolution of melanoma resistance reveals therapeutic opportunities.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The evolution of melanoma resistance reveals therapeutic opportunities.
@en
type
label
The evolution of melanoma resistance reveals therapeutic opportunities.
@en
prefLabel
The evolution of melanoma resistance reveals therapeutic opportunities.
@en
P1433
P1476
The evolution of melanoma resistance reveals therapeutic opportunities.
@en
P2093
Darrin D Stuart
Meghna Das Thakur
P304
P356
10.1158/0008-5472.CAN-13-1633
P407
P577
2013-10-04T00:00:00Z